Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer


Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.

Related Videos
Michael Hagensee, MD, PhD, Louisiana State University Health, New Orleans School of Medicine